Skip to search formSkip to main contentSkip to account menu

HAVCR2 gene

Known as: T-CELL IMMUNOGLOBULIN AND MUCIN DOMAINS-CONTAINING PROTEIN 3, HAVCR2, TIMD3 
This gene plays a role in macrophage and T helper cell activation.
National Institutes of Health

Related topics

Related topics

5 relations
Hepatitis A Virus Cellular Receptor 2Immune System ProcessesImmune ToleranceMyeloid Cell Activation Process

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PTPN2 Mediates Production of Exhausted T Cells and Antitumor Immunity.
Ptpn2 deletion increased the ratio of TIM3+ terminally exhausted to SLAMF6+ progenitor CD8+ T cells. 
2018
2018
Prognostische Relevanz von TIM3 bei Nierenzellkarzinomen
Hintergrund. Die Immun-CheckpointTherapie (ICI) hat die Behandlungsoptionen für Patienten mit fortgeschrittenem… 
2017
2017
Elucidation of the Plasmacytoid Dendritic Cell Response to HIV-1
Plasmacytoid dendritic cells (pDCs) are a specialized type I interferon (TI-IFN) producing cell of the innate immune system; they… 
2017
2017
Abstract 3656: Implication for checkpoint therapeutics: Expression of co-stimulatory and co-inhibitory molecules in melanoma cells
Melanoma is one of the deadliest forms of skin cancer, with a dim prognosis when metastasized, leading to the highest number of… 
2016
2016
Abstract 3214: A fully human anti-TIM3 antibody with co-stimulatory activity
Targeting immune checkpoint molecules has been demonstrated to have significant benefit to patients with cancer. One such… 
Review
2015
Review
2015
Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
2015
2015
Tim-3 blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV+ patients
T cell immunoglobulin and mucin domain (Tim) 3 and programmed death 1 (PD‐1) are co‐inhibitory receptors involved in the so… 
2015
2015
PD-1: Dual guard for immunopathology
Despite remarkable medical development, chronic infectious diseases caused by the infections with persistent pathogens such as… 
2015
2015
Abstract 4706: TCR engineered adoptive T-cell therapy for lung cancer is augmented by combined PD1 and TIM3 antibody blockade
INTRODUCTION: ACT has shown great promise in melanoma and hematologic malignancies; however one major limitation of engineered T… 
2011
2011
Tim1 and Tim3 are not essential for experimental allergic asthma
Background Initial studies suggested that polymorphisms in Tim1 and Tim3 contribute to the development of airway hyperreactivity… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)